Drugs / FFP104
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02465944 | Jan 2016 → Aug 2017 | Crohn disease | Fast Forward Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02193360 | May 2015 → Aug 2017 | primary biliary cholangitis | Fast Forward Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FFP104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465944 ↗ |
| Action | Inhibit | “CD40-antagonist Mab” NCT02193360 ↗ |
| Modality | Monoclonal antibody | “CD40-antagonist Mab” NCT02193360 ↗ |
| Route | Intravenous | “multiple weekly or biweekly i.v. doses of FFP104” NCT02193360 ↗ |
| Target | CD40 | “CD40-antagonist Mab” NCT02193360 ↗ |